KRAS and neoplasm: KRAS and BRAF alterations are also commonly found in CRC, where KRAS mutation leads to the constitutive activation of the RAS signaling pathway, cell survival, and proliferation [216,217], whereas BRAF alterations, particularly the V600E mutation, activate the MAPK signaling pathway which contribute to tumor growth [218].